Trump expected to pick Dr. Heidi Overton to lead FDA

Overton Expected to Become Next FDA Commissioner

Qwenews.com – President Donald Trump is poised to name Dr. Heidi Overton as the next head of the US Food and Drug Administration, according to two sources with direct knowledge of the matter. Bloomberg News broke the story first. The White House had not responded to a comment request at the time of reporting.

A Confirmation Fight Looms in the Senate

An official nomination would trigger another potentially contentious vote before the Senate health committee. Just this month, lawmakers narrowly approved Dr. Erica Schwartz to lead the US Centers for Disease Control and Prevention — but only after Republican Senator Bill Cassidy stalled the process, citing his longstanding objections to the administration’s vaccine stance. Shortly after that confirmation, Trump signed an executive order designed to overhaul the nation’s childhood immunization schedule, drawing sharp rebuke from Cassidy and much of the public health community. Overton was positioned among senior officials flanking the president in the Oval Office when he signed that directive.

From the Domestic Policy Council to the Agency

Overton currently serves as deputy director of the White House Domestic Policy Council, where she has been a central architect of the administration’s health care agenda. A physician by training, she previously held a role in Trump’s first administration before moving to the America First Policy Institute, a conservative think tank, where she ultimately directed its health policy center.

The selection follows roughly three months since Dr. Marty Makary, Trump’s first FDA commissioner, resigned under intense White House pressure. Health officials in the administration have searched for a replacement since Makary’s May departure, prioritizing candidates who could steady an agency plagued by repeated personnel churn and internal disputes over policy direction. The pool narrowed quickly to a small set of finalists, including Overton and prominent cancer physician Dr. Jeff Vacirca, sources said.

White House Alliances Shaped the Outcome

Overton ultimately carried substantial backing inside the White House, one source familiar with the process noted. That support was anchored in her close working relationship with chief of staff Susie Wiles and a preexisting personal rapport with Trump himself. Agriculture Secretary Brooke Rollins, who has collaborated closely with the Health and Human Services Department over recent months, was regarded as another pivotal ally. Rollins and Overton had previously worked side by side during Trump’s first term and later at the America First Policy Institute.

Skepticism Within the MAHA Movement

The choice could nonetheless provoke unease among figures aligned with the “Make America Healthy Again” movement. Some remain wary of Overton’s role in earlier decisions this year to walk back the most contentious elements of HHS Secretary Robert F. Kennedy Jr.’s agenda — particularly around vaccines — and to align with the agriculture industry on key pesticide questions. Although Overton and Kennedy have collaborated closely on a range of health priorities, insiders familiar with the dynamic raised doubts about how the two would function together once Overton transitions from the White House into an FDA position that is, in the bureaucratic hierarchy, subordinate to Kennedy.